Biogen Inc. (BIT:1BIIB)

Market Cap	15.96B
Revenue (ttm)	9.08B
Net Income (ttm)	1.37B
Shares Out	n/a
EPS (ttm)	9.36
PE Ratio	11.66
Forward PE	8.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39
Average Volume	46
Open	106.65
Previous Close	103.60
Day's Range	105.65 - 108.20
52-Week Range	101.40 - 206.70
Beta	n/a
RSI	49.95
Earnings Date	Jul 31, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD